Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Updates from CheckMate 040 in Asian HCC patients

Thomas Yau • 4 Jul 2020
ESMO WCGIC 2020
Gastrointestinal Cancer Liver Cancer Antibodies Ipilimumab Nivolumab
CheckMate 040

Thomas Yau, MD, MBBS, MRCP, FRCP, of the University of Hong Kong, Hong Kong, China, discusses the efficacy and safety of nivolumab and ipilumumab in Asian patients with advanced hepatocellular carcinoma (HCC) as evaluated in the CheckMate 040 study (NCT01658878). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Thomas Yau

1:02
Future directions of HCC treatment
Thomas Yau • 6 Jul 2020
3:46
CheckMate 459: updates on nivolumab monotherapy for HCC
Thomas Yau • 27 Sep 2019

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals